BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing. The Biosciences segment provides instruments that enable the handling of cells and rare samples, and rapid transfer of liquids and reagents, as well as downstream analysis platforms. The Bioautomation segment offers end-to-end products and services in precision dispensing, advanced sample preparation, multiplex analysis and assay miniaturization, diagnostic and medical device manufacturing for life science and diagnostic industries. It primarily serves medical, pharmaceutical, and cosmetic industries. The company offers its products through sales organizations, as well as through an extensive distributor network. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
| 3.534 | |
| 3.534 | |
| - | |
| 3.534 | |
| 3.534 | |
| 2.9-6.346 | |
| 249 M | |
| 69 075 K | |
| 2 423 M | |
| 2.357 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
CARLSBAD, Calif., June 02, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet ...
Granted by the United States Patent and Trademark Office, with extensions filed globally, the patent covers an approach that gives laboratories the ability to increase productivity for time and cost e...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
